Quest PharmaTech to Receive $3,000,000 to Develop Oncology Products Based on its SonoLight ... ( EDMONTON Dec. 17 / Quest PharmaTe...)

Quest PharmaTech to Receive $3,000,000 to Develop Oncology Products Based on its SonoLight Technology

Date:12/17/2007

EDMONTON, Dec. 17 /PRNewswire-FirstCall/ - Quest PharmaTech Inc. (TSX Venture Exchange: QPT) today announced that it has signed an agreement with a multinational technology development company (the "Investor") to receive $3,000,000 to develop oncology products based on its SonoLight Technology. Under the terms of the agreement, Quest Pharma Tech Inc. ("Quest" or the "Company") has already received $1,000,000; and the balance of $2,000,000 will be paid within the next twelve months. In return for this non-equity funding, the Investor who requested to remain anonymous, will receive 35 percent of all future net revenue from the commercialization of Quest's oncology products. This agreement does not preclude Quest from out-licensing the oncology applications of SonoLight Technology to a third party.

The Company's lead oncology product from the SonoLight platform, SL052, is anticipated to enter a Phase I clinical trial for photodynamic therapy treatment of prostate cancer during the second half of 2008. The Company is also evaluating the same technology for the treatment of lung cancer and peritoneal carcinomatosis.

"I can't think of a better holiday present to our shareholders than establishing an accelerated oncology development program," said Dr. Madi R. Madiyalakan, Chief Executive Officer of Quest Pharma Tech Inc. "We are optimistic about the potential of both our oncology products and our dermatology program. Additionally, we believe that our partnerships with Paramount BioSciences and KMH Co. Ltd. will help us achieve our long-term growth objectives, including share price appreciation."

About Quest PharmaTech Inc.

The Corporation is a publicly traded (TSX Venture Exchange: QPT), Alberta-based pharmaceutical company committed to build shareholder value through discovery, development, and commercialization of new pharmaceutical products. It is developing a series of products for the treatment of cancer and dermatological conditions
'/>"/>

SOURCE Quest PharmaTech Inc.
Copyright©2007 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2
Related biology technology :

1. ImmuneRegen Responds to Defense Threat Reduction Agency Request for Information
2. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
3. Quest Diagnostics to Speak at the 2007 UBS Global Life Sciences Conference
4. VioQuest Pharmaceuticals to Present at BIO InvestorForum in San Francisco
5. Quest Diagnostics Joins National ePrescribing Patient Safety Initiative (NEPSI)
6. University HealthSystem Consortium Chooses SciQuest to Optimize Medical Research Procurement
7. VioQuest Pharmaceuticals to Present at the Paramount BioSciences Healthcare Conference
8. Sinovac Requests Extension for Annual Shareholders Meeting
9. Maryland Stem Cell Commission Issues Nationwide Request for Applications for New Post-Doctoral Fellowship Grants
10. AmSurg Selects SciQuest Eprocurement Solution to Automate Purchasing of Medical Goods and Services
11. WuXi PharmaTech Schedules 2007 Second Quarter Earnings Release on Thursday, September 6, 2007

Post Your Comments:

(Date:6/19/2013)... , June 19, 2013 Biotechnology industry pioneer ... with financial software provider BlackLine Systems and enterprise ... SAP ) for a webinar next week entitled "No ... from BlackLine and SAP to Help Keep Its Account Reconciliations ... http://photos.prnewswire.com/prnh/20061117/LAF027LOGO ) The webinar, geared at finance, ...

(Date:6/19/2013)... (PRWEB) June 18, 2013 A new ... materials, costs and other trends will highlight technical sessions ... California this fall. In its 33rd year, the three-day ... an exhibition of key suppliers, approximately 100 technical presentations ... SPIE, the international society for optics and photonics , ...

(Date:6/18/2013)... KONG, June 18, 2013 China Cord Blood ... "Company"), China,s leading provider of cord blood collection, laboratory ... services, today announced its preliminary unaudited financial results for ... 2013 ended March 31, 2013. Fourth ... the fourth quarter of fiscal 2013 increased by 33.3% ...

(Date:6/18/2013)... 18, 2013 The human skin is the ... an important human body part. Similar to the liver, or ... to function, repair and grow. Recent reports from the mankatofreepress.com ... is just as important as other life supporting organs. The ... in skin cell reproduction, increase the appearance of skin, and ...

[0] Amgen Joins BlackLine Systems, SAP for Webinar on Automating Account Reconciliations [0] ‘Big Glass’ and Visions for the Future are on the Program for SPIE Photomask Technology [0] China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2013 [0] Natural Acne Remedies Through Diet, Probiotic Action Shares New Insight on What Foods May Help Lead to Clear Skin

... Halozyme Therapeutics, Inc. (Nasdaq: HALO ) ... the first patient received subcutaneous (SC) MabThera (rituximab), an ... Enhanze(™ technology (rHuPH20, recombinant human hyaluronidase). This ... Herceptin ® SC (trastuzumab), to enter a Phase ...

... Transgenomic, Inc. (OTC Bulletin Board: TBIO ) ... officer, will deliver the Company,s corporate presentation at Lippert/Heilshorn ... on Thursday, February 17, 2011 at 11:30 a.m. Eastern ... webcast with slide presentation at: www.transgenomic.com , or ...

... ROCKVILLE, Md., Feb. 15, 2011 Neuralstem, Inc. (NYSE ... business leader Stanley I. Westreich to its Board of ... comprised of a majority of independent directors. ... of Neuralstem,s Board of Directors and the Company,s Chief ...

Cached Biology Technology:Halozyme Announces Roche Doses First Patient in Phase 3 Clinical Trial With Subcutaneous MabThera® (rituximab) 2 Halozyme Announces Roche Doses First Patient in Phase 3 Clinical Trial With Subcutaneous MabThera® (rituximab) 3 Halozyme Announces Roche Doses First Patient in Phase 3 Clinical Trial With Subcutaneous MabThera® (rituximab) 4 Transgenomic to Present at the Lippert/Heilshorn Life Sciences & Medtech Virtual Conference on February 17 2 Transgenomic to Present at the Lippert/Heilshorn Life Sciences & Medtech Virtual Conference on February 17 3 Former Capital One Director and Business Leader Stanley I. Westreich Joins Neuralstem's Board 2 Former Capital One Director and Business Leader Stanley I. Westreich Joins Neuralstem's Board 3

Halozyme Announces Roche Doses First Patient in Phase 3 Clinical Trial With Subcutaneous MabThera® (rituximab)Transgenomic to Present at the Lippert/Heilshorn Life Sciences & Medtech Virtual Conference on February 17 Former Capital One Director and Business Leader Stanley I. Westreich Joins Neuralstem's Board

(Date:6/19/2013)... of mammals and birds are threatened with extinction as a ... and colleagues from The Ohio State University in the US. ... exponential growth of the human population will continue to pose ... not appear to be a threshold above which population growth ... is published online in Springer,s journal, Human Ecology . ...

(Date:6/19/2013)... New York, NY, June 19, 2013 A ... Diabetes Research in Helmholtz Zentrum Mnchen, Germany, is ... autoantibodies and the risk of developing type 1 ... into possible preventions for the disease. The study, ... Progression to Diabetes in Children," was published today ...

(Date:6/19/2013)... offers further proof that the divergence of humans from ... was profoundly influenced by mutations to DNA sequences that ... The study, published June 9 in Nature Genetics ... of genes must play an important role in evolution ... in the proteins produced by genes. Indeed, human and ...

Breaking Biology News(10 mins):Are we pushing animals over the edge? 2 New data on islet autoantibodies in young children defines early type 1 diabetes development 2 New research backs theory that genetic 'switches' play big role in human evolution 2 New research backs theory that genetic 'switches' play big role in human evolution 3

[0] Are we pushing animals over the edge?[0] New data on islet autoantibodies in young children defines early type 1 diabetes development [0] New research backs theory that genetic 'switches' play big role in human evolution

... Bette Korber is part of an international team of ... trial of a mosaic HIV vaccine candidate. The vaccine ... causes AIDS by attempting to address one of the ... extensive genetic diversity. The team and its efforts ...

... UPTON, NY Scientists at the U.S. Department of ... have discovered a key difference in the way human ... unwanted proteins marked with a "kiss of death" ... critical difference, described in a paper published online October ...

... TAMPA, Fla., Sept. 22 Lockheed Martin (NYSE: ... new DNA analysis system that has potential to transform how ... in support of their missions. The prototype, called ... Biometric Consortium Conference special session on Rapid DNA. The ...

Cached Biology News:Consortium to design human trials of mosaic HIV vaccine 2 Key difference in how TB bacteria degrade doomed proteins 2 Lockheed Martin and ZyGEM Accelerate DNA Identification for Law Enforcement, Homeland Security and Defense Communities 2 Lockheed Martin and ZyGEM Accelerate DNA Identification for Law Enforcement, Homeland Security and Defense Communities 3

Consortium to design human trials of mosaic HIV vaccine Key difference in how TB bacteria degrade doomed proteins Lockheed Martin and ZyGEM Accelerate DNA Identification for Law Enforcement, Homeland Security and Defense Communities

... no longer need to perform time consuming and ... Mutation Surveyor, any found variants of the sample ... indicated in our mutation electropherogram as a sharp ... bi-directional analysis mode is over 99%, with sensitivity ...

...

... 220-240 V, is used for biolistic particle ... device employs an adjustable helium pulse to ... microcarriers from the inner wall of a ... This system has a 2 square-centimeter target ...

Mouse monoclonal antibody raised against a full length recombinant YARS. NCBI Entrez Gene ID = YARS...

Biology Products:

Mutation Surveyor from SoftGenetics, LLC.Finnigan LTQ FT from Thermo Scientific Helios Gene Gun System, 220-240 V from Bio-Rad Mouse Anti-Human YARS Monoclonal Antibody, Unconjugated, Clone 2F3 from Abnova Corporation